2015 Conferences and Events > European HIV Hepatitis Co-infection (EHHC) Conference > European HIV Hepatitis Co-infection (EHHC) Conference - Presentations >

European HIV Hepatitis Co-infection (EHHC) Conference - Thursday 10 December 2015

Date: 10 - 11 December 2015

Venue: Queen Elizabeth II Conference Centre, London


Please select a day by clicking on one of the links below.

Pre-Conference Clinical Course

Welcome address from the Co-Chairs

Dr Ranjababu Kulasegaram, St Thomas' Hospital, London, UK
Dr Andrew Freedman, Cardiff University School of Medicine, UK

Basics of hepatitis B diagnostics
Dr Emma Page, Leeds Teaching Hospitals NHS Trust, UK

Overview of biomarkers for viral evolution and liver disease progression in hepatitis B and hepatitis C
Dr Philippe Halfon, Hôpital Européen Marseille, France

Low-level transaminitis in an HIV-mono-infected patient
Dr Emmanuel Tsochatzis, University College London, UK

Exploring viral kinetics in hepatitis
Dr Valeria Cento, Universita degli Studi di Roma Tor Vergata, Italy

Pre-Conference Nurses' Course

Welcome address from the Co-Chairs

Mr Ricky Gellissen, National HIV Nurses Association (NHIVNA)
Ms Sally Bufton, British Association for the Study of the Liver Nurse Forum

An overview of blood results, interpretation and what this means for the CNS in clinic
Mrs Janet Catt, Royal Free London NHS Trust, UK

Patients' experience of hepatitis C
Dr Magdalena Harris, London School of Hygiene and Tropical Medicine, UK

Hepatitis C and cirrhosis
Ms Lynda Greenslade, Royal Free London NHS Trust, UK

Acute hepatitis C infection in HIV-positive MSM partner notification and issues of re-infection
Mr Ricky Gellissen, Imperial College Healthcare NHS Trust, London, UK
Dr Matthew Grundy-Bowers, City University London, UK

The arguments for treating promptly vs waiting for eligibility for DAAs
Dr Emma Thomson, University of Glasgow Centre for Virus Research, UK

European HIV Hepatitis Co-infection (EHHC) Conference

Introduction and Welcome

Dr Sanjay Bhagani, Chair, EHHC Conference Steering Committee
The Rt Hon Lord Fowler, BHIVA Patron

Plenary Session 1

State of the art in hepatitis C treatment
Dr Sanjay Bhagani, Royal Free London NHS Trust, UK

Should we be doing baseline resistance testing?
Dr Emma Thomson, University of Glasgow Centre for Virus Research, UK

Plenary Session 2

Hepatitis C treatment failure: what next?
Dr Ashley Brown, Imperial College Healthcare NHS Trust, London, UK

Pharmacoeconomics of hepatitis C treatment
Dr Andrew Hill, University of Liverpool, UK

Plenary Session 3

Data from real-life cohorts - France
Professor Lionel Piroth, Centre Hospitalier Universitaire, Dijon, France

Data from real-life cohorts - Germany
Dr Stefan Mauss, Center for HIV and Hepatogastroenterology, Düsseldorf, Germany

Data from real-life cohorts - UK
Dr Andrew Ustianowski, North Manchester General Hospital, UK

Data from real-life cohorts - Spain
Dr Karin Neukam, Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain

Data from real-life cohorts - Ukraine
Dr Sergii Filippovych, Aids Alliance, Kiev, Ukraine

Clinical case presentations

Treatment of recurrent hepatitis C infection after liver transplantation in an HIV-positive patient
Dr Emma Hathorn, University Hospitals Birmingham NHS Foundation Trust, UK

Use of resistance testing for salvage DAA therapy
Dr Federico Garcia, CHUG Hospital Universitario San Cecilio, Granada, Spain

Hep today, gone tomorrow
Dr James Millard, Brighton and Sussex Medical School, UK

Nephrotic syndrome in a patient with HCV/HIV co-infection
Dr Ramona Malek, Imperial College Healthcare NHS Trust, London, UK